PRECIGEN INC (PGEN) Stock Price & Overview
NASDAQ:PGEN • US74017N1054
The current stock price of PGEN is 3.42 USD. Today PGEN is down by -2.56%. In the past month the price decreased by -26.61%. In the past year, price increased by 90%.
PGEN Key Statistics
- Market Cap
- 1.21B
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -1.28
- Dividend Yield
- N/A
PGEN Stock Performance
PGEN Stock Chart
PGEN Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to PGEN. When comparing the yearly performance of all stocks, PGEN is one of the better performing stocks in the market, outperforming 89.83% of all stocks.
PGEN Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to PGEN. PGEN scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
PGEN Earnings
On March 9, 2026 PGEN reported an EPS of -1.06 and a revenue of 2.92M. The company missed EPS expectations (-993.91% surprise) and beat revenue expectations (472.94% surprise).
PGEN Forecast & Estimates
9 analysts have analysed PGEN and the average price target is 8.67 USD. This implies a price increase of 153.51% is expected in the next year compared to the current price of 3.42.
For the next year, analysts expect an EPS growth of -155.49% and a revenue growth 312.21% for PGEN
PGEN Groups
Sector & Classification
PGEN Financial Highlights
Over the last trailing twelve months PGEN reported a non-GAAP Earnings per Share(EPS) of -1.28. The EPS decreased by -204.76% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -248.66% | ||
| ROE | -1017.16% | ||
| Debt/Equity | 2.22 |
PGEN Ownership
PGEN Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.34 | 401.392B | ||
| AMGN | AMGEN INC | 16.55 | 202.383B | ||
| GILD | GILEAD SCIENCES INC | 16.52 | 184.425B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 25.4 | 126.804B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.57 | 81.619B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 42.95 | 42.754B | ||
| INSM | INSMED INC | N/A | 31.007B | ||
| NTRA | NATERA INC | N/A | 28.197B | ||
| BIIB | BIOGEN INC | 11.85 | 27.651B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.24 | 23.485B | ||
| MRNA | MODERNA INC | N/A | 21.714B | ||
| EXAS | EXACT SCIENCES CORP | 340.18 | 19.732B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 19.591B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About PGEN
Company Profile
Precigen, Inc. is a biotechnology company, which engages in the research and development of synthetic biology technologies. The company is headquartered in Germantown, Maryland and currently employs 143 full-time employees. The company went IPO on 2013-08-08. The Company’s proprietary technology platforms develop product candidates designed to target urgent and intractable diseases in its core therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. The company has developed a pipeline of therapies across multiple indications. The Company’s segments include Biopharmaceuticals and Exemplar. The Biopharmaceuticals segment is primarily comprised of the Company's legal entities as well as royalty interests in therapeutics and therapeutic platforms from companies not controlled by the Company. The Exemplar is composed of Exemplar Genetics LLC, doing business as Precigen Exemplar, its wholly owned subsidiary focused on developing research models and services for healthcare research applications.
Company Info
IPO: 2013-08-08
PRECIGEN INC
20374 Seneca Meadows Parkway
Germantown MARYLAND 20876 US
CEO: Helen Sabzevari
Employees: 143
Phone: 13015569900
PRECIGEN INC / PGEN FAQ
What does PGEN do?
Precigen, Inc. is a biotechnology company, which engages in the research and development of synthetic biology technologies. The company is headquartered in Germantown, Maryland and currently employs 143 full-time employees. The company went IPO on 2013-08-08. The Company’s proprietary technology platforms develop product candidates designed to target urgent and intractable diseases in its core therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. The company has developed a pipeline of therapies across multiple indications. The Company’s segments include Biopharmaceuticals and Exemplar. The Biopharmaceuticals segment is primarily comprised of the Company's legal entities as well as royalty interests in therapeutics and therapeutic platforms from companies not controlled by the Company. The Exemplar is composed of Exemplar Genetics LLC, doing business as Precigen Exemplar, its wholly owned subsidiary focused on developing research models and services for healthcare research applications.
Can you provide the latest stock price for PRECIGEN INC?
The current stock price of PGEN is 3.42 USD. The price decreased by -2.56% in the last trading session.
Does PGEN stock pay dividends?
PGEN does not pay a dividend.
What is the ChartMill rating of PRECIGEN INC stock?
PGEN has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What is PRECIGEN INC worth?
PRECIGEN INC (PGEN) has a market capitalization of 1.21B USD. This makes PGEN a Small Cap stock.
Who owns PRECIGEN INC?
You can find the ownership structure of PRECIGEN INC (PGEN) on the Ownership tab.